Trial Profile
A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Vorinostat (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 16 Aug 2019 Status changed from active, no longer recruiting to completed.
- 11 Sep 2017 Planned End Date changed from 31 Aug 2017 to 31 Jan 2023.
- 08 May 2017 Planned End Date changed from 30 Jun 2017 to 31 Aug 2017.